Search results for "immune checkpoint inhibitor"

Muscle Loss Double-Whammy: Sarcopenia Triggers Faster Progression in Lung Cancer Patients on Immunotherapy

Muscle Loss Double-Whammy: Sarcopenia Triggers Faster Progression in Lung Cancer Patients on Immunotherapy

Muscle mass in lung cancer patients may play a decisive role in determining the success of immunotherapy. A new study indicates that patients with...
Stomach Cancer Immunotherapy: Different Effects on Men and Women... Effective for Men, but 'Not So Much' for Women

Stomach Cancer Immunotherapy: Different Effects on Men and Women... Effective for Men, but 'Not So Much' for Women

A study has revealed that the therapeutic effects of 'immune checkpoint inhibitors ', which are gaining attention as the next breakthrough in stomach...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
Rznomics to Present Oral Report on Breakthrough Anti-Cancer Gene Therapy at AACR

Rznomics to Present Oral Report on Breakthrough Anti-Cancer Gene Therapy at AACR

Rznomics, a biotechnology company specializing in RNA-based gene therapies, announced on March 5 that it has been...
Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears

Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears

Among breast cancers, ‘triple-negative breast cancer ’ is particularly challenging to treat.
Abl Bio Confirms Positive Effects of Cancer Drug 'ABL111' in Phase 1b Clinical Trial

Abl Bio Confirms Positive Effects of Cancer Drug 'ABL111' in Phase 1b Clinical Trial

Abl Bio announced on the 7th that it has confirmed positive anti-cancer efficacy in the dose expansion cohort of the...
Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals

Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals

Ligand Pharmaceuticals announced on the 5th that it has recruited Dr. Han Jin-hwan, formerly of Merck, as the head of...
Languages

ENGLISH

English (US)

ASIAN

日本語Tiếng ViệtBahasa Indonesia中文 (简体, 中国大陆)

EUROPEAN

РусскийEspañol (España)Français (France)

MIDDLE_EAST_AFRICA

العربية